Доступ предоставлен для: Guest
International Journal of Medicinal Mushrooms
Главный редактор: Solomon P. Wasser (open in a new tab)

Выходит 12 номеров в год

ISSN Печать: 1521-9437

ISSN Онлайн: 1940-4344

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 1.2 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 1.4 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.3 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00066 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.34 SJR: 0.274 SNIP: 0.41 CiteScore™:: 2.8 H-Index: 37

Indexed in

Cancer Risk Reduction by Intake of Mushrooms and Clinical Studies on EEM

Том 7, Выпуск 3, 2005, 347 pages
DOI: 10.1615/IntJMedMushrooms.v7.i3.110
Get accessDownload

Краткое описание

An epidemiological survey was carried out concerning farmers producing Flammulina velutipes (W.Curt.:Fr.) Singer “Enokitake” from 1972 to 1986 in Nagano prefecture, Japan. Cancer death rates of the farmers were lower than those of the average rate of total Nagano prefecture. Intake of edible mushrooms was suggested as being effective for risk reduction of cancer.
This was an ecological study. Next, a case-control study was made to elucidate the relationship between risk reduction of cancer and intake of edible mushrooms on stomach cancer in the same prefecture from 1998 to 2OO2.The odds ratio (OR) of subjects who were practically not ingesting mushrooms at all was 1.00; the OR of those ingesting Hypsizygus marmoreus (Peck) H.E.Bigelow (Bunashimeji) or Pholiota nameko (T.Ito) S.Ito et S.Imai (Nameko) more than once a week was 0.57 and 0.56, respectively. Whereas the OR of subjects taking mushrooms less than once a week was 1.00, the OR of those taking Flammulina velutipes more than three times a week was 0.66, and the OR of those taking Lentinus edodes (Berk.) Singer “Shiitake” more than three times a week was 0.95. It can be concluded that the intake of Hypsizygus marmoreus, Flammulina velutipes, and Pholiota nameko has the possibility of decreasing stomach cancer incidence.
Studies on antitumor activities of mushrooms were carried out in the National Cancer Center, Japan. Many antitumor polysaccharides and protein-bounded polysaccharides were isolated from mushrooms.
Based on these studies, extracts were made from Hypsizygus marmoreus and Flammulina velutipes, and a preparation called “EEM” (extracts of edible mushrooms) was supplied. Clinical studies of EEM were performed to investigate the effectiveness for cancer patients. Positive effects of EEM were studied on the cachexia of advanced cancer patients in comparison with MPA (methylacetoxyprogestrone). EEM revealed better results than MPA in clinical response, performance status (PS), and quality of life (QOL). Another clinical study was made with a combination therapy of EEM and cancer chemotherapy agents for advanced cancer patients. The clinical response rate, PS, and QOL of the patients treated with combination therapy (EEM and anticancer drugs) were better than those of the patients treated with anticancer drugs alone. The positive effects of EEM were also investigated for a precancerous lesion on the esophageal mucosa. After the patients of grade II of atypical hyperplasia on the esophageal mucosa were administered EEM tablets for 6 months, a positive effect of EEM was found.

ЦИТИРОВАНО В
  1. Moradali Mohammad-Fata, Mostafavi Hossein, Ghods Shirin, Hedjaroude Ghorban-Ali, Immunomodulating and anticancer agents in the realm of macromycetes fungi (macrofungi), International Immunopharmacology, 7, 6, 2007. Crossref

  2. Morris Humberto J., Llauradó Gabriel, Beltrán Yaixa, Lebeque Yamila, Bermúdez Rosa C., García Nora, Gaime-Perraud Isabelle, Moukha Serge, The Use of Mushrooms in the Development of Functional Foods, Drugs, and Nutraceuticals, in Wild Plants, Mushrooms and Nuts, 2016. Crossref

  3. Badalyan Susanna M., Barkhudaryan Anush, Rapior Sylvie, Recent Progress in Research on the Pharmacological Potential of Mushrooms and Prospects for Their Clinical Application, in Medicinal Mushrooms, 2019. Crossref

  4. Stajić Mirjana, Vukojević Jelena, Ćilerdžić Jasmina, Mushrooms as Potential Natural Cytostatics, in Medicinal Mushrooms, 2019. Crossref

Портал Begell Электронная Бибилиотека e-Книги Журналы Справочники и Сборники статей Коллекции Цены и условия подписки Begell House Контакты Language English 中文 Русский Português German French Spain